A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)

NCT07222189 | Not Yet Recruiting Phase 2 DMC FDA Drug

• 3 other identifiers: LTS196892025-522511-42U1111-1321-1765
• Study Type: interventional
• Target: 325
• Locations: 0 countries
• Sites: N/A

Brief Summary

LTS19689 is a multinational, multicenter extension study to evaluate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn's disease (CD) or ulcerative colitis (UC) who completed the 52-week treatment period (on balinatunfib or placebo) in the parent studies, SPECIFI-CD (DRI18212) or SPECIFI-UC (DRI17822), respectively.

• The primary objective of this study is to assess the long-term safety and tolerability of different doses of balinatunfib in participants with CD or UC, as measured by the number and percentage of participants with CD or UC with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) during the study period.
• The study will consist of 2 independent cohorts through the study given the distinct nature of each disease:
• CD Cohort: comprised of CD participants enrolled from SPECIFI-CD (DRI18212).
• UC Cohort: comprised of UC participants enrolled from SPECIFI-UC (DRI17822).
• The study will consist of the following study periods for each cohort:
• A Double-Blind (DB) treatment period of up to 104 weeks for eligible participants from the DB maintenance phases of the respective parent studies.
• An Open-Label (OL) treatment period of up to 104 weeks for:
• Eligible participants from either the DB or OL periods of the parent studies,
• Eligible participants who meet escape criteria at any time during the DB period of the LTS19689.
• A 2-week follow-up period following the End of Treatment (EOT). The study duration will be up to 107 weeks, with the treatment duration up to 104 weeks.

Conditions

Colitis Ulcerative; Crohn's Disease

Outcome Measures

Primary Outcomes (2)

• Number of participants with Crohn's Disease with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)

  Up to End of Study (approximately 106 weeks)

• Number of participants with ulcerative colitis with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)

  Up to End of Study (approximately 106 weeks)

Secondary Outcomes (6)

• Proportion of participants with Crohn's Disease in endoscopic remission based on simple endoscopic score for Crohn's disease (SES-CD)

  Week 52

• Proportion of participants with Crohn's Disease in endoscopic remission based on simple endoscopic score for Crohn's disease (SES-CD)

  Week 104

• Proportion of participants with Crohn's Disease in clinical remission based on Crohn's disease activity index (CDAI)

  Week 52

• Proportion of participants with Crohn's Disease in clinical remission based on Crohn's disease activity index (CDAI)

  Week 104

• Proportion of participants with ulcerative colitis in clinical remission based on modified Mayo Score (mMS)

  Week 52

Study Arms (8)

CD cohort: balinatunfib dose regimen 1

EXPERIMENTAL

Participants will receive balinatunfib dose regimen 1

Drug: balinatunfib

CD cohort: balinatunfib dose regimen 2

EXPERIMENTAL

Participants will receive balinatunfib dose regimen 2

Drug: balinatunfib

CD cohort: balinatunfib dose regimen 3

EXPERIMENTAL

Participants will receive balinatunfib dose regimen 3

Drug: balinatunfib

CD cohort: Placebo

PLACEBO COMPARATOR

Participants will receive balinatunfib-matching placebo

Drug: balinatunfib-matching placebo

UC cohort: balinatunfib dose regimen 1

EXPERIMENTAL

Participants will receive balinatunfib dose regimen 1

Drug: balinatunfib

UC cohort: balinatunfib dose regimen 2

EXPERIMENTAL

Participants will receive balinatunfib dose regimen 2

Drug: balinatunfib

UC cohort: balinatunfib dose regimen 3

EXPERIMENTAL

Participants will receive balinatunfib dose regimen 3

Drug: balinatunfib

UC cohort: Placebo

PLACEBO COMPARATOR

Participants will receive balinatunfib-matching placebo

Drug: balinatunfib-matching placebo

Interventions

balinatunfib DRUG

Pharmaceutical form:Tablet -Route of administration:Oral

Also known as: SAR441566

CD cohort: balinatunfib dose regimen 1; CD cohort: balinatunfib dose regimen 2; CD cohort: balinatunfib dose regimen 3; UC cohort: balinatunfib dose regimen 1; UC cohort: balinatunfib dose regimen 2; UC cohort: balinatunfib dose regimen 3

balinatunfib-matching placebo DRUG

Pharmaceutical form:Tablet -Route of administration:Oral

CD cohort: Placebo; UC cohort: Placebo

Eligibility Criteria

• Age: 19 Years - 77 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants are eligible to be included in the study only if all of the following criteria apply:
• Participants with Crohn's Disease (CD) or ulcerative colitis (UC) who completed treatment at Week 52 of the SPECIFI-CD (DRI18212) or SPECIFI-UC (DRI17822) studies, respectively:
• Participants with CD
• who complete double-blinded treatment at Week 52 of SPECIFI-CD (DRI18212) study;
• who complete open label treatment and achieve the appropriate outcomes at Week 52 of SPECIFI-CD (DRI18212) study.
• Participants with UC
• who complete double-blinded treatment at Week 52 of SPECIFI-UC (DRI17822) study;
• who complete open label treatment and achieve the appropriate outcomes at Week 52 of the SPECIFI-UC (DRI17822) study.
• Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women participants should not be pregnant or breastfeeding

You may not qualify if:

• Participants who developed a new medical condition or a change in status of an established medical condition which (per Investigator's medical judgment) would adversely affect the participation in this study or would require permanent IMP discontinuation.
• Participants who permanently discontinued IMP during the parent study or temporarily discontinued IMP for more than 14 consecutive calendar days by the time of Day 1 of LTS19689.
• Participants who, during their participation in the parent study, developed an adverse event (AE) or a serious adverse event (SAE) deemed related to balinatunfib, which in the opinion of the Investigator could indicate that continued treatment with balinatunfib may present an unreasonable risk for the participant.
• Participants who in the parent study had documented nonadherence to IMP or to standard therapies for CD or UC, or who used a prohibited medication concomitant with IMP or during a temporary IMP discontinuation period.
• The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Sponsors & Collaborators

• Sanofi: lead

MeSH Terms

Conditions

Colitis, Ulcerative; Crohn Disease

Condition Hierarchy (Ancestors)

Colitis; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Inflammatory Bowel Diseases; Colonic Diseases; Intestinal Diseases

Central Study Contacts

Trial Transparency email recommended (Toll free for US & Canada)

CONTACT

800-633-1610; Contact-US@sanofi.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Blinding is not applicable for open-label arms.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 27, 2025
• First Posted: October 29, 2025
• Study Start (Estimated): May 12, 2026
• Primary Completion (Estimated): May 10, 2030
• Study Completion (Estimated): May 10, 2030
• Last Updated: December 15, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share